Soluble CD40 ligand levels in essential hypertensive men: Evidence of a possible role of insulin resistance

American Journal of Hypertension

Volumn 22, Issue 9, 2009, Pages 1007-1013

  Penno, Giuseppe ^a   Pucci, Laura ^a   Dell'Omo, Giulia ^a   Lucchesi, Daniela ^a   Miccoli, Roberto ^a   Del Prato, Stefano ^a   Solini, Anna ^a   Pedrinelli, Roberto ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; GLUCOSE; INSULIN;

ADULT; AGE; AGED; ALBUMINURIA; ARTERIAL WALL THICKENING; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; ESSENTIAL HYPERTENSION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING;

ADULT; AGED; BLOOD GLUCOSE; CAROTID ARTERY, COMMON; CD40 LIGAND; HUMANS; HYPERTENSION; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; SOLUBILITY; TUNICA INTIMA;

EID: 69249209633     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2009.121     Document Type: Article

References (34)

1. de Lemos JA, Zirlik A, Schönbeck U, Varo N, Murphy SA, Khera A, McGuire DK, Stanek G, Lo HS, Nuzzo R, Morrow DA, Peshock R, Libby P. Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 2005; 25: 2192-2196.
2. Lobbes MB, Lutgens E, Heeneman S, Cleutjens KB, Kooi ME, van Engelshoven JM, Daemen MJ, Nelemans PJ. Is there more than C-reactive protein and fibrinogen? The prognostic value of soluble CD40 ligand, interleukin-6 and oxidized low-density lipoprotein with respect to coronary and cerebral vascular disease. Atherosclerosis 2006; 187:18-25.
3. Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR, Fernández-Cruz A, Veves A, Jarolim P, Varo JJ, Goldfine A, Horton E, Schönbeck U. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 2003; 107:2664-2669.
4. Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 2004; 109:2524-2528.
5. Santilli F, Davì G, Consoli A, Cipollone F, Mezzetti A, Falco A, Taraborelli T, Devangelio E, Ciabattoni G, Basili S, Patrono C. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol 2006; 47:391-397.
6. Cipollone F, Chiarelli F, Davì G, Ferri C, Desideri G, Fazia M, Iezzi A, Santilli F, Pini B, Cuccurullo C, Tumini S, Del Ponte A, Santucci A, Cuccurullo F, Mezzetti A. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 2005; 48:1216-1224.
7. Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Maerz W, Hombach V, Koenig W. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003; 107:1954-1957.
8. Angelico F, Alessandri C, Ferro D, Pignatelli P, Del Ben M, Fiorello S, Cangemi R, Loffredo L, Violi F. Enhanced soluble CD40L in patients with the metabolic syndrome: Relationship with in vivo thrombin generation. Diabetologia 2006; 49:1169-1174.
9. Basili S, Pacini G, Guagnano MT, Manigrasso MR, Santilli F, Pettinella C, Ciabattoni G, Patrono C, Davì G. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 2006; 48:2531-2538.
10. Gokulakrishnan K, Deepa R, Mohan V, Gross MD. Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome- the Chennai Urban Rural Epidemiology Study. Metab Clin Exp 2006; 55:237-242.
11. Akinci G, Coskun S, Akinci B, Hekimsoy Z, Bayindir P, Onur E, Ozmen B. Atherosclerosis risk factors in children of parents with the metabolic syndrome. Atherosclerosis 2007; 194:e165-e171.
12. Vaidyula VR, Rao AK, Mozzoli M, Homko C, Cheung P, Boden G. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes 2006; 55:202-208.
13. Yan JC, Ma GS, Wu ZG, Kong XT, Zong RQ, Zhan LZ. Increased levels of CD40-CD40 ligand system in patients with essential hypertension. Clin Chim Acta 2005; 355:191-196.
14. Patel JV, Lim HS, Nadar S, Tayebjee M, Hughes EA, Lip GY. Abnormal soluble CD40 ligand and C-reactive protein concentrations in hypertension: relationship to indices of angiogenesis. J Hypertens 2006; 24:117-121.
15. Sonmez A, Dogru T, Yilmaz MI, Ocal R, Ozgurtas T, Kilic S, Eyileten T, Tasci I, Erbil K, Kocar IH. Soluble CD40 ligand levels in patients with hypertension. Clin Exp Hypertens 2005; 27:629-634.
16. Desideri G, Cipollone F, Valeri L, Grassi D, Necozione S, Croce G, Passacquale G, Garofalo A, Lippi C, Mezzetti A, Ferri C. Enhanced plasma soluble CD40 ligand levels in essential hypertensive patients with blunted nocturnal blood pressure decrease. Am J Hypertens 2007; 20:70-6; discussion 77.
17. Dell'Omo G, Penno G, Del Prato S, Mariani M, Pedrinelli R. Dysglycaemia in non-diabetic hypertensive patients: comparison of the impact of two different classifications of impaired fasting glucose on the cardiovascular risk profile. J Hum Hypertens 2009; 23:332-338.
18. Ferroni P, Guagnano MT, Falco A, Paoletti V, Manigrasso MR, Michetti N, Santilli F, Guadagni F, Basili S, Davì G. Association of low-grade inflammation and platelet activation in patients with hypertension with microalbuminuria. Clin Sci 2008; 114:449-455.
19. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26:3160-3167.
20. National Kidney Disease Education Program. Estimating GFR. Suggestion for Laboratories. . Accessed 16 December 2008.
21. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998; 21:2191-2192.
22. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 2003; 17: 305-322.
23. McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA, Duncan AW. Diagnosing insulin resistance in the general population. Diabetes Care 2001; 24:460-464.
24. Anwaruddin S, Askari AT, Topol EJ. Redefining risk in acute coronary syndromes using molecular medicine. J Am Coll Cardiol 2007; 49:279-289.
25. Ferroni P, Guadagni F. Soluble CD40L and its role in essential hypertension: diagnostic and therapeutic implications. Cardiovasc Hematol Disord Drug Targets 2008; 8:194-202.
26. Mari A, Pacini G, Brazzale AR, Ahrén B. Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance test. Diabetologia 2005; 48:748-751.
27. Desideri G, Ferri C. Effects of obesity and weight loss on soluble CD40L levels. JAMA 2003; 289:1781-1782.
28. Guldiken S, Demir M, Arikan E, Turgut B, Azcan S, Gerenli M, Tugrul A. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: Soluble CD40 ligand and high-sensitivity C-reactive protein. Thromb Res 2007; 119:79-84.
29. Keaney JF, Lipinska I, Larson MG, Dupuis J, Freedman JE, Hamburg NM, Massaro JM, Rong J, Sutherland P, Vita JA, Vasan RS, Benjamin EJ. Clinical correlates, heritability, and genetic linkage of circulating CD40 ligand in the Framingham Offspring Study. Am Heart J 2008; 156:1003-1009.e1.
30. Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens 2008; 21:500-508.
31. Pedrinelli R, Dell'Omo G, Di Bello V, Pellegrini G, Pucci L, Del Prato S, Penno G. Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol 2004; 24:2414-2419.
32. Tsioufis C, Dimitriadis K, Taxiarchou E, Vasiliadou C, Chartzoulakis G, Tousoulis D, Manolis A, Stefanadis C, Kallikazaros I. Diverse associations of microalbuminuria with C-reactive protein, interleukin-18 and soluble CD 40 ligand in male essential hypertensive subjects. Am J Hypertens 2006; 19:462-466.
33. Filozof C, Gómez-Garre D, Reinares L, González-Rubio ML, Muñoz-Pacheco P, Rueda A, Alvarez-Arcaya A, Calle-Pascual AL, Fernández-Cruz A. Relationship between plasma levels of soluble CD40L and insulin sensitivity and insulin secretion status in non-diabetic dyslipidemic patients. Diabetes Res Clin Pract 2008; 79:48-55.
34. Razani B, Chakravarthy MV, Semenkovich CF. Insulin resistance and atherosclerosis. Endocrinol Metab Clin North Am 2008; 37:603-21, viii.